Keywords: fda, oks, aventis, taxotere, prostate, cancer, food
FDA OKs Aventis' Taxotere for prostate cancer
Article | 24 May 2004
The US Food and Drug Administration has approved the use of Aventis' Taxotere (docetaxel) Injection Concentrate, in combination with prednisone, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
